What is the minimum investment required for PCD Pharma Franchise?

The minimum investment typically ranges from ₹2–5 lakhs, depending on territory size, product selection and initial stock planning. Our team will help structure this based on your goals.

What documents are required to become a franchise partner?

You will need a valid Drug License, GST registration and basic KYC documents. Our team will guide you through every step of the documentation process.

What kind of support and training do you provide?

We provide product training, sales guidance, marketing materials, doctor coverage strategies, and ongoing business support through dedicated account managers.

How are territories allocated and protected?

Territories are allocated based on mutual agreement and market mapping. We offer genuine monopoly rights with clear documentation to avoid internal competition.

What is the expected profit margin and ROI timeline?

Average profit margins range from 25–30%, with typical ROI timelines between 12–18 months, depending on your execution and territory potential.

How do you ensure product quality and compliance?

All products are manufactured in WHO-GMP certified facilities with 100% quality testing, robust documentation and DCGI approvals as applicable.

What is the delivery timeline and process?

Dispatch timelines depend on order size and location, but we maintain a strong track record of timely delivery across India with proper packaging and logistics partners.

Vials

Zax-500

Ceftriaxone 500 mg

Pack: 1x1
Format: With Carton

MRP₹52.56

A mid-strength, third-generation cephalosporin antibiotic injection formulated for the effective management of various systemic and localized bacterial infections. Zax-500 contains Ceftriaxone 500mg, providing a balanced therapeutic dose for older children, adolescents, and adults with moderate infectious conditions.

About The Product

Key Benefits

Potent Bactericidal Mechanism

Ceftriaxone 500mg acts by inhibiting the synthesis of the bacterial cell wall. By binding to specific penicillin-binding proteins (PBPs), it prevents the bacteria from forming a stable structure, leading to cell rupture and the rapid elimination of the pathogen.

Broad-Spectrum Clinical Coverage

This formulation is highly effective against a wide array of Gram-positive and Gram-negative aerobic bacteria. It is a reliable choice for treating common community-acquired infections and various hospital-acquired pathogens.

Stability Against Bacterial Resistance

Zax-500 is engineered to be highly resistant to many beta-lactamase enzymes. This allows the antibiotic to remain active against bacterial strains that have developed defenses against older penicillins and first-generation cephalosporins.

Deep Tissue and Fluid Distribution

The active ingredient demonstrates superior penetration into nearly all body tissues and fluids. Its ability to cross the blood-brain barrier makes it an essential tool for treating infections involving the central nervous system.

Optimized Therapeutic Half-Life

Ceftriaxone is characterized by an extended duration of action in the body. This allows for effective once-daily or twice-daily dosing schedules, ensuring consistent antibacterial pressure at the site of infection.

Rapid Systemic Bioavailability

As an injectable medication, Zax-500 bypasses the gastrointestinal tract to provide immediate and complete absorption into the bloodstream, making it ideal for patients who cannot tolerate oral medications.

Indication Moderate Respiratory Tract Infections, Complicated Urinary Tract Infections, Skin and Soft Tissue Infections, Bone and Joint Infections, Early-stage Septicemia, Post-Operative Infection Prophylaxis.

Indications

Moderate Respiratory Tract Infections
Complicated Urinary Tract Infections
Skin and Soft Tissue Infections
Bone and Joint Infections
Early-stage Septicemia
Post-Operative Infection Prophylaxis.

Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.

Zax-500